NCT07293754 An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
| NCT ID | NCT07293754 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Repertoire Immune Medicines |
| Condition | Advanced Malignant Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-12-12 |
| Primary Completion | 2028-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2025-12-12 with a primary completion date of 2028-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Eligibility Criteria
Inclusion Criteria * Histologically or cytologically confirmed locally advanced or metastatic solid tumors that is not amenable to curative treatment. * At least one measurable lesion per RECIST v1.1 as assessed by the investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function as defined in the trial protocol. * Ability to provide written informed consent and comply with trial procedures. Exclusion Criteria: * History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies considered cured and not expected to require active therapy (for example, certain skin cancers or in situ malignancies) per protocol. * Known active leptomeningeal disease or uncontrolled central nervous system metastases. * Active, clinically significant, autoimmune diseases requiring systemic immunosuppressive therapy. * Prior allogenic organ transplantation * Clinically significant uncontrolled medical or psychiatric condition, that in the opinion of the investigator, would increase risk or interfere with trial participation. * Other protocol-defined inclusion and exclusion criteria apply
Frequently Asked Questions
Who can join the NCT07293754 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Malignant Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07293754 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07293754 currently recruiting?
Yes, NCT07293754 is actively recruiting participants. Visit ClinicalTrials.gov or contact Repertoire Immune Medicines to inquire about joining.
Where is the NCT07293754 trial being conducted?
This trial is being conducted at Grand Rapids, United States, Lake Success, United States, San Antonio, United States, Dublin, Ireland and 8 additional locations.
Who is sponsoring the NCT07293754 clinical trial?
NCT07293754 is sponsored by Repertoire Immune Medicines. The trial plans to enroll 150 participants.